Clinical trials: ASCVD
ASCVD, Elevated Cholesterol
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability…
- Trial name
- ORION-10 (NCT03399370)
- Testing
- Inclisiran Sodium
- Where
- 145 sites in United States
- Volunteers
- 1,561 people
- Sponsor
- The Medicines Company
ASCVD, Risk Factor, Cardiovascular
Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy…
- Conditions
- ASCVD, Risk Factor, Cardiovascular, Elevated Cholesterol
- Trial name
- ORION-11 (NCT03400800)
- Testing
- Inclisiran Sodium
- Where
- 70 sites in Czechia, Germany and 5 more
- Volunteers
- 1,617 people
- Sponsor
- The Medicines Company
ASCVD
High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients
This study will evaluate the efficacy and safety of high-intensity rosuvastatin and moderate-intensity rosuvastatin/ezetimibe in ASCVD patients.
- Trial name
- NCT03494270
- Testing
- Rosuvamibe, Monorova
- Where
- South Korea
- Volunteers
- 270 people
- Sponsor
- Yuhan Corporation
Metabolic Syndrome, ASCVD
Cardiometabolic Syndrome Response to Therapeutic Lifestyle Changes
Intensive lifestyle intervention has shown to be effective in high risk patient populations and has gathered support from leaders-as outlined in the 2015 consensus paper by the Cardiometabolic Health Alliance.
- Conditions
- Metabolic Syndrome, ASCVD, Lifestyle Risk Reduction
- Trial name
- COSMETIC (NCT04093440)
- Testing
- lifestyle modification
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Holy Cross Hospital, Florida
Dyslipidemia, Subclinical hypothyroïdism
Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study)
In ASCVD patients complicated with subclinical hypothyroidism, the percentage of those who did not reach the target of lipid-lowering therapy (LDL-C>1.8mmol/L) is usually higher than that in population with normal thyroid…
- Conditions
- Dyslipidemia, Subclinical hypothyroïdism, Statin, ASCVD
- Trial name
- NCT03606824
- Testing
- Pitavastatin and levothyroxine
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Shaochun.Li